Non-targeted metabolite profiling and specific targeted discrimination strategy for quality evaluation of Cortex Phellodendri from different varieties

Cortex Phellodendri is derived from two species of Phellodendron amurense Rupr. and Phellodendron chinense Schneid. Traditionally, the two species are utilized interchangeably under the name of “huangbo” in the clinic because they are believed to share the same clinical efficacy. However, the chemical analysis in vitro couldn't directly reflect the pharmacological effects. Therefore, whether the constituents could be absorbed into the blood becomes the uppermost problem to account for the clinical efficacy differences of the two species. Therefore, a rapid and sensitive approach to differentiate the two species of Cortex Phellodendri based on non-targeted metabolite profiling and the specific targeted discrimination strategy was first established. Samples from different cultivars were clearly discriminated by principal component analysis and orthogonal partial least squares discriminant analysis. 17 prototype compounds and 22 metabolites contributing to the group separation were identified and tentatively characterized, three of which were found for the first time. Moreover, six of them were screened out as the chemical markers which contribute most to the differences between the two species. Taken together, the application of the non-targeted metabolite profiling and specific targeted discrimination strategy is suitable for the assessment of Cortex Phellodendri.